Parameters of glucose and lipid metabolism at the fasted state in drug-naïve first-episode patients with psychosis: Evidence for insulin resistance

Psychiatry Research

Volumn 229, Issue 3, 2015, Pages 901-904

  Petrikis, Petros ^a   Tigas, Stelios ^a   Tzallas, Alexandros T ^b   Papadopoulos, Ioannis ^a   Skapinakis, Petros ^a   Mavreas, Venetsanos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Epirus Institute of Technology Arta   (Greece)

Author keywords

Cholesterol; Diabetes; Dyslipidemia; First episode; Metabolism; Schizophrenia

Indexed keywords

C PEPTIDE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; INSULIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTATIC MODEL ASSESSMENT INDEX; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC PARAMETERS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS; BLOOD; CASE CONTROL STUDY; DIET RESTRICTION; HOMEOSTASIS; METABOLISM; PHYSIOLOGY;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CASE-CONTROL STUDIES; CHOLESTEROL; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYDROCORTISONE; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; PSYCHOTIC DISORDERS; TRIGLYCERIDES;

EID: 84941261732     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.07.041     Document Type: Article

References (34)

1. Andreasen C.N., Nopoulos P., Magnotta V., Pierson R., Ziebell S., Ho B.-Ch Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol. Psychiatry 2011, 70:672-679.
2. Arranz B., Posel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., Navarro M.A., San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naïve first-episode schizophrenia patients. J. Clin. Psychiatry 2004, 65:1335-1342.
3. Balf G., Stewart T.D., Whitehead R., Baker R.A. Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Prim. Care Companion J. Clin. Psychiatry 2008, 10:15-24.
4. Brown S., Birtwistle J., Roe L., Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 1999, 29:697-701.
5. Chen S., Broqueres-You D., Yang G., Wang Z., Li Y., Wang N., Zhang X., Yang F., Tan Y. Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naïve first-episode patients with schizophrenia. Psychiatry Res. 2013, 210:825-829.
6. Correll U.C., Robinson G.D., Schooler R.N., Brunette F.M., Mueser T.K., Rosenheck A.R., Marcy P., Addington J., Estroff E.S., Robinson J., Penn L.D., Azrin S., Goldstein A., Severe J., Heinssen R., Kane M.J. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders. Baseline results from the RAISE-ETP study. JAMA Psychiatry 2014, 71:1350-1363.
7. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004, 36:131-137.
8. Fernandez-Egea E., Bernardo M., Donner Th., Conget I., Parellada E., Justicia A., Estmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naïve individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194:434-438.
9. Fooley D.L., Morley K.I., Carroll K.E., Moran J., McGorry P.D., Murphy B.P. Successful implementation of cardiometabolic monitoring of patients treated with antipsychotics. Med. J. Aust. 2009, 1:518-519.
10. Greenwood T.A., Light G.A., Swerdlow N.R., Radant A.D., Braff D.L. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One 2012, 7(1):e29630. 10.1371/journal.pone.0029630.
11. Haffner S.M., Miettinen H., Stern M.P. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997, 20:1087-1092.
12. Hansen Th., Ingason A., Djurovic S., Melle I., Fenger M., Gustafsson O., Jacobsen D.K., Rasmussen B.H., Tosato S., Rietschel M., Frank J., Owen M., Bonetto C., Suvisaari J., Thygesen H.J., Pétursson H., Lönnqvist J., Sigurdsson E., Giegling I., Craddock N., O'Donovan C.M., Ruggeri M., Cichon S., Ophoff A.R., Pietiläinen O., Peltonen L., Nöthen M.M., Rujescu D., Clair St.D., Collier A.D., Andreassen A.O., Werge T. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol. Psychiatry 2011, 70:59-63.
13. Joutinen J., Hakko H., Meyer-Rochow B., Rasanen P., Timonen M. The study-70 research group. Body mass index (BMI) of drug-naïve psychotic adolescents based on a population of adolescent psychiatric inpatients. Eur. Psychiatry 2008, 23:521-526.
14. Kirkpatrick B., Garcia-Rizo C., Tang K., Fernandez-Egea E., Bernardo M. Cholesterol and triglycerides in antipsychotic-naïve patients with nonaffective psychosis. Psychiatry Res. 2010, 178:559-561.
15. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br. J. Psychiatry 2004, 184:64-66.
16. Lammers C.H., Garcia-Borreguero D., Schmider J., Gotthardt U., Dettling M., Holsboer F., Heuser I.J. Combined dexamethasone/corticotrophin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol. Psychiatry 1995, 38:803-807.
17. Li L., Li X., Zhou W., Messina J.F. J. Endocrinol. 2013, 217:175-184.
18. Lin P.L., Shuldiner A.R. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr. Res. 2010, 123:234-243.
19. Manzanares N., Monseny R., Ortega.L., Montalvo I., Franch J., Gutieres-Zotes A., Reynolds R.M., Walker B., Vilella E., Labad J. Unhealthy lifestyle in early psychosis: the role of life stress and the hypothalamic-pituary-adrenal axis. Psychoneuroendocrinology 2014, 39:1-10.
20. Mitchell A.J., Vancampfort D., De Herdt A., Yu W., De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? a comparative meta-analysis of first episode, untreated and treated patients. Schizophr. Bull. 2013, 39:295-305.
21. Nielsen J., Skadhede S., Correl l C.U. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010, 35:1997-2004.
22. Oud J.T.M., Meyboom-de Jong B. Somatic diseases in patients with schizophrenia in general praxis: their prevalence and health care. BMC Fam. Pract. 2009, 10:32-41.
23. Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther. Adv. Psychopharmacol. 2013, 3:33-51.
24. Perez-Iglesias R., Mata I., Pelayo-Teran J.M., Amado J.A., Garcia-Unzueta M.T., Berja A., Martinez-Garcia O., Vasquez-Barquero J.L., Crespo- Facorro B. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophr. Res. 2009, 107:115-121.
25. Perez-Iglesias R., Vazquez-Berquero J.L., Amado J.A., Berja A., Garcia-Unzueta M.T., Pelayo-Teran J.M., Carrasco-Marin E., Mata I., Crespo-Facorro B. Effect of antipsychotics on peptides involved in energy balance in drug-naïve psychotic patients after 1 year of treatment. J. Clin. Psychopharmacol. 2008, 28:289-295.
26. Rubi B., Ljubicic S., Pournourmohammadi S., Garobbio S., Armanet M., Bartley C., Maechler P. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J. Biol. Chem. 2005, 280:36824-36832.
27. Ryan C.M.M., Collins P., Thakore H.J. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am. J. Psychiatry 2003, 160:284-289.
28. Saari K., Lindeman S., Koponen H., Jokelainen J., Isohanni M. Higher serum triglyceride levels in early-onset schizophrenia. Am. J. Psychiatry 2004, 161:176.
29. Sengupta S., Parilla-Escobar M., Klink R., Fathalli F., Ng Y.K., Strip E., Batista T., Malla A., Joober R. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?. Schizophr. Res. 2008, 102:329-336.
30. Spelman L., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet. Med. 2007, 24:481-485.
31. Wu X., Huang Z., Wu R., Zhong Z., Wei Q., Wang H., Diao F., Wang J., Zheng L., Zhao J., Zhang J. The comparison of glucometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls. Schizophr. Res. 2013, 150:157-162.
32. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituary adrenal axis in the developmental course of schizophrenia. Annu. Rev. Clin. Psychol. 2008, 4:4189-4216.
33. Verma K.S., Subramaniam M., Liew A. Metabolic risk factors in drug-naïve patients with first episode psychosis. J. Clin. Psychiatry 2009, 70:997-1000.
34. Vancampfort D., Wampers M., Mitchell A., Correll C., Herdt A., Probst M., Hert M. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first- episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013, 12:240-250.